Should You Search Brand Names and Generic Names?

If a product has a generic name, do you still need its brand names?

A medicine can have an international or generic name and also be marketed under one or many proprietary brand or trade names. Similar naming problems arise with medical devices, commercial technologies, software, assessment tools, and other interventions.

If you are searching the literature, which name should you use?

Searching only the generic name may seem scientifically cleaner, but publications and other records do not necessarily use only that name. Conversely, searching every brand ever associated with a product can create unnecessary complexity and ambiguity. The appropriate strategy depends on what names appear in relevant records, where and when the product was used, and how the database indexes it.

Search both when either name could appear without the other

One intervention can have several searchable identities

Generic and brand names are different naming systems

For medicines, the generic or nonproprietary name identifies the active substance independently of a particular manufacturer's brand. A brand or trade name is a proprietary name under which a product is marketed.

These naming systems coexist in real-world literature. Research examining free-text medication data has found both generic and trade names in substantial use, illustrating why normalization systems such as RxNorm explicitly map trade names to generic drug concepts.

Literature-search guidance likewise recommends including both generic and trade names when selecting medication keywords.

Why searching only the generic name can miss records

An article may mention a brand prominently in the title or abstract while the generic name appears only elsewhere in the full text, supplementary material, indexing, or not at all in the searchable fields available to you.

The reverse can also happen. A publication may report only the generic name and never mention the brand.

Empirical evidence from healthcare communication shows that clinicians themselves use generic and trade names differently, and medication nomenclature research has documented large numbers of trade names associated with generic drugs.

A sensitive free-text strategy therefore needs to reflect the naming forms actually encountered in relevant records.

Do not stop at generic plus brand

For some interventions, two naming categories are still insufficient. Early trials may use a development code before a generic name becomes established. Older literature may use a former name. Chemical identifiers, abbreviations, salts, formulations, or active ingredients may also provide useful retrieval routes depending on the question.

A 2026 case study comparing search approaches for a network meta-analysis found an older publication whose title and abstract used only a drug development code rather than the later generic or brand name. That record was retrievable in some databases because additional indexed or substance-name information was available, while other database representations lacked those details.

This is a particularly clear reminder that a product's searchable identity can change over its development history.

If earlier terminology matters, consider whether you also need historical names for the intervention.

Brand names can vary by country

A product marketed under one proprietary name in one country may use another elsewhere. If your review is geographically broad, searching only the brand familiar in your own market can create a hidden geographic bias in retrieval.

Brand naming can be more complicated still. Research comparing approved medication names across countries has documented identical or similar brand names associated with different active ingredients in different markets.

Some brand names are dangerously ambiguous search terms

A brand may also be an ordinary word, resemble another product name, or have unrelated commercial uses. Searching it unrestricted can therefore produce substantial noise.

Drug-name extraction research has documented false matches caused by similarities between trade and generic names, while medication search-system research has likewise identified brand names and short synonyms that generate problematic inexact matches.

When a brand is ambiguous, test it separately. Phrase searching, contextual drug terms, field restrictions, or proximity operators may improve precision depending on the database.

This is a practical instance of the broader problem of similar or ambiguous terms that can retrieve different concepts.

Controlled vocabulary provides another retrieval route

Free-text drug names should usually be considered alongside appropriate database indexing. PRESS recommends using both relevant subject headings and free-text terms for search concepts and checking whether headings are missing, overly broad, overly narrow, or require explosion.

A controlled-vocabulary heading can retrieve records even when the terminology appearing in titles and abstracts varies. But indexing does not eliminate the need for free text. Newly added records may not yet have complete indexing, and some relevant names or concepts may not map perfectly onto one heading.

This is why understanding the distinction between keywords and subject headings matters when searching named products.

Build a name map before building the Boolean string

For a consequential search, create a small inventory of the intervention's identities before deciding which ones belong in the final query.

Use authoritative naming sources

Do not generate brand-name lists from memory. For medications, authoritative regulatory and terminology resources can help establish relationships among active ingredients and proprietary products. Depending on the jurisdiction and purpose, useful sources may include drug regulators, official product databases, RxNorm, and database thesauri.

RxNorm is particularly relevant to U.S. clinical drug terminology because it provides normalized drug names and links among vocabularies, including relationships involving branded products. Research using RxNorm has demonstrated how its relationships can be used to derive trade names associated with generic drugs.

For international reviews, no single national product database should be assumed to provide every brand used worldwide.

Search the names as alternatives, but preserve conceptual distinctions

When several verified names identify the same intervention, they are commonly combined within the intervention concept block using OR.

A simplified structure might look like:

("generic name" OR "brand A" OR "brand B" OR "development code")

The actual syntax should be adapted to the database. Some names may need phrase searching, field tags, truncation, or other handling.

Importantly, this structure does not imply that every branded formulation is automatically interchangeable for the purposes of your research question. Eligibility may depend on dose, formulation, delivery route, combination ingredients, indication, or other intervention characteristics.

Combination products require additional care

A brand name can identify a combination product containing more than one active ingredient. Searching the brand alone may retrieve the combination, while searching one generic ingredient may retrieve many products outside your intervention definition.

Research on generic and trade-name recognition has long noted that combination products complicate the relationship between proprietary and generic terminology.

For combination products, verify every active ingredient and determine whether the review concerns the branded combination, the ingredients individually, the drug class, or some combination of these.

Do not assume more brand names always mean a better search

A medicine with a long market history may have many brands across manufacturers and jurisdictions. Adding every possible proprietary name can make the search unwieldy and introduce ambiguous terms.

Prioritize names that plausibly appear in the literature covered by your review. Examine known relevant studies, regulatory histories, trial registries, previous reviews, and terminology databases. Then test questionable names for unique relevant retrieval.

The objective is not to compile the world's longest pharmaceutical alias list. It is to represent the intervention sufficiently well that naming variation does not become an accidental exclusion criterion.

Building a search around an intervention with several names

If the generic name alone misses the early development literature, the code is not decorative redundancy. It performs a distinct retrieval function.

Common mistakes when searching generic and brand names

Search the intervention across its naming history

When an intervention can appear under multiple names, treat terminology mapping as part of search development. Start with the standardized name, then investigate how the intervention was identified during development, commercialization, international use, and database indexing.

Known relevant studies are particularly useful. Their bibliographic records tell you which identities actually matter for retrieval.

Before finalizing a search for a named product

Questions about searching generic and brand names

Search the names the literature actually uses

How to Cite This Guide

This guide is intended to be read, shared, and used in research, teaching, and academic work. If you draw on its ideas, explanations, or other content, please acknowledge the source by citing the guide. Doing so gives appropriate credit and helps your readers locate the original resource.